

# Amgen-Horizon Deal May Signal FTC's Return To Bargaining

BYLINE ARTICLES | LESS THAN 1 MIN READ

September 13, 2023


By: Laura C. Onken

On Sept. 1, just over a week before trial was slated to begin, the Federal Trade Commission and several states **agreed to settle** their challenge to Amgen Inc.'s proposed acquisition of Horizon Therapeutics, allowing the transaction to close.

[Click here to read the article.](#)

## Related People

---



Laura C. Onken

# Related Services

---

Antitrust

To subscribe to our publications, [click here](#).

## Featured Insights

- SABA North America Annual Conference 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- Navigating Compliance: How the 2025 Hart-Scott-Rodino Updates Are Impacting Businesses  
**WEBINAR    ANTITRUST**
- NJSBA Annual Meeting and Convention 2025  
**SPEAKING ENGAGEMENT    INTELLECTUAL PROPERTY**
- Hartford HealthCare Black and Red Gala 2025  
**SPONSORSHIP    ANTITRUST**
- Informa CompLaw Antitrust West Coast Conference 2025  
**SPEAKING ENGAGEMENT    ANTITRUST**
- AHLA Health Care Transactions Program 2025  
**SPONSORSHIP    ANTITRUST**
- IAM Live: Auto IP USA 2025  
**SPEAKING ENGAGEMENT    INTELLECTUAL PROPERTY**
- ACI 21st Annual Paragraph IV Conference  
**SPEAKING ENGAGEMENT    INTELLECTUAL PROPERTY**
- A Check-in on the Structural Presumption: What Have We Learned and Where Are We Headed?  
**WEBINAR    ANTITRUST**

- Biosimilars Litigation and Client Counseling

**BYLINE ARTICLES**

© 2025 Axinn, Veltrop & Harkrider LLP. All Rights Reserved